Amishi Y. Shah, MD, MD Anderson Cancer Center
Articles by Amishi Y. Shah, MD, MD Anderson Cancer Center
Incorporating Treatment Advances Into mRCC Management
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Emerging Therapies for Relapsed/Refractory mRCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.
Relapsed/Refractory mRCC: Sequencing Therapy
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.
Treatment Approaches for Relapsed/Refractory mRCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center An overview of treatment options for previously treated metastatic renal cell carcinoma.
Adjuvant Therapy Approaches for Operable RCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center A summary of current therapies and ongoing investigations of adjuvant therapy for patients with operable renal cell carcinoma.
Therapies Under Investigation for Frontline mRCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Novel therapies currently being investigated as frontline options for metastatic renal cell carcinoma.
Favorable-Risk mRCC: Treatment Approaches
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center A panel discussion regarding individual preferences for treating favorable-risk metastatic renal cell carcinoma.
Favorable-Risk mRCC: When to Initiate Therapy
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.
Intermediate/Poor-Risk mRCC: Treatment Selection
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.
Intermediate/Poor-Risk mRCC: I-O/I-O Vs I-O/TKI Therapy
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.
I-O/TKI Regimens for Metastatic RCC: Dosing Strategies
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.
The CLEAR Trial in Metastatic RCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.
Frontline Metastatic RCC: Nivolumab Plus Cabozantinib
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.
Frontline Metastatic RCC: Pembrolizumab Plus Axitinib
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.
Frontline Metastatic RCC: Nivolumab Plus Ipilimumab
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.
Frontline Treatment Advances in Metastatic RCC
ByMartin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Robert Alter, MD, John Theurer Cancer Center,Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre,Amishi Y. Shah, MD, MD Anderson Cancer Center,Sandy Srinivas, MBBS, Stanford Cancer Center Dr. Sandy Srinivas comments on treatment approaches for frontline metastatic renal cell carcinoma based on the emergence of novel combination regimens that introduce immunotherapy.
Adjuvant Therapy Approaches for Operable RCC
Frontline Metastatic RCC: Nivolumab Plus Cabozantinib
Frontline Metastatic RCC: Pembrolizumab Plus Axitinib
The CLEAR Trial in Metastatic RCC
I-O/TKI Regimens for Metastatic RCC: Dosing Strategies
Therapies Under Investigation for Frontline mRCC